Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7516031 | 1.00 | RCE1 (0.46) | RCE1HTTTSHRALDH1A1LMNA | |
| SCHEMBL23030029 | 0.88 | MAPT (0.47) | RCE1HTTTSHRALDH1A1LMNA | |
| SCHEMBL7155541 | 0.85 | MAPT (0.53) | RCE1HTTTSHRALDH1A1LMNA | |
| SCHEMBL17663535 | 0.85 | MAPT (0.53) | RCE1HTTTSHRALDH1A1LMNA | |
| SCHEMBL13174889 | 0.84 | SLC1A3 (0.50) | RCE1HTTTSHRALDH1A1LMNA | |
| SCHEMBL20403336 | 0.84 | SLC1A3 (0.50) | RCE1HTTTSHRALDH1A1LMNA | |
| SCHEMBL178116 | 0.83 | SLC1A3 (0.49) | RCE1HTTTSHRALDH1A1LMNA | |
| SCHEMBL15013883 | 0.83 | RCE1 (0.54) | RCE1HTTTSHRALDH1A1LMNA | |
| SCHEMBL875014 | 0.83 | RCE1 (0.54) | RCE1HTTTSHRALDH1A1LMNA | |
| SCHEMBL874697 | 0.83 | RCE1 (0.54) | RCE1HTTTSHRALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240216291-A1 | Nucleic Acid Containing Nanoparticles | BIO TRIP B V (NL) | 2024-07-04 | — | — | US | disclosed |
| EP-4358936-A1 | NUCLEIC ACID CONTAINING NANOPARTICLES | Bio-TRIP B.V. (NL) | 2024-05-01 | — | — | EP | disclosed |
| CN-117545467-A | Nucleic acid-containing nanoparticles | 比奥-特里普公司 | 2024-02-09 | — | — | CN | disclosed |
| WO-2022268913-A1 | NUCLEIC ACID CONTAINING NANOPARTICLES | BIO-TRIP B.V. (NL) | 2022-12-29 | — | — | WO | disclosed |
| EP-2590968-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | Novartis AG (CH) | 2013-05-15 | — | — | EP | disclosed |
| EP-2215054-B8 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | EVOTEC AG (DE) | 2012-02-08 | — | — | EP | disclosed |
| WO-2012004217-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-01-12 | — | — | WO | disclosed |
| EP-2215054-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | Renovis, Inc. (US) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009064449-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS, INC. (US) | 2009-05-22 | — | — | WO | disclosed |
| EP-0730860-B1 | Mixed micelles | HOFFMANN LA ROCHE (CH) | 2002-01-02 | — | — | EP | disclosed |
| EP-1162979-A2 | CYCLIC GLYCEROPHOSPHATES AND ANALOGS THEREOF | YEDA RESEARCH AND DEVELOPMENT Co. LTD. (IL) | 2001-12-19 | — | — | EP | disclosed |
| EP-1162959-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLIC GLYCEROPHOSPHATES AND ANALOGS THEREOF FOR PROMOTING NEURAL CELL DIFFERENTIATION | YEDA RESEARCH AND DEVELOPMENT Co. LTD. (IL) | 2001-12-19 | — | — | EP | disclosed |
| WO-2000057865-A9 | PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLIC GLYCEROPHOSPHATES AND ANALOGS THEREOF FOR PROMOTING NEURAL CELL DIFFERENTIATION | YEDA RES & DEV (IL) | 2001-11-15 | — | — | WO | disclosed |
| WO-2000057865-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLIC GLYCEROPHOSPHATES AND ANALOGS THEREOF FOR PROMOTING NEURAL CELL DIFFERENTIATION | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2000-10-05 | — | — | WO | disclosed |
| WO-2000057864-A2 | CYCLIC GLYCEROPHOSPHATES AND ANALOGS THEREOF | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2000-10-05 | — | — | WO | disclosed |
| US-5747066-A | PHOSPHATIDES, BILE ACID SALT OR DIHEXANOYLLECITHIN | HOFFMANN-LA ROCHE INC. (US) | 1998-05-05 | — | — | US | disclosed |
| EP-0730860-A2 | Mixed micelles | F. HOFFMANN-LA ROCHE AG (CH) | 1996-09-11 | — | — | EP | disclosed |
| EP-0393512-A1 | New 1,3-dioxolane-2-yl derivatives of 2-picolylamine | J. URIACH & CIA. S.A. (ES) | 1990-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216291-A1 | Nucleic Acid Containing Nanoparticles | APOB, APOL1, TLR3 | RCE1 3827/4885HTT 1965/4885TSHR 3256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.